Fosdagrocorat对比泼尼松或安慰剂治疗类风湿关节炎:随机双盲多中心IIb期研究
该12周IIb期随机对照试验纳入323例中重度类风湿关节炎患者,比较fosdagrocorat(1、5、10、15 mg)、泼尼松(5、10 mg)或安慰剂每日一次。第8周时,fosdagrocorat 10 mg和15 mg的ACR20应答优于安慰剂,15 mg不劣于泼尼松10 mg;骨形成标志物P1NP变化在1、5、10 mg剂量达非劣于泼尼松5 mg。不良事件组间相似。
要点
- fosdagrocorat 10 mg和15 mg的ACR20应答优于安慰剂
- fosdagrocorat 15 mg的ACR20应答不劣于泼尼松10 mg
- fosdagrocorat 1、5、10 mg的P1NP变化非劣于泼尼松5 mg
核心结论
- 在中重度类风湿关节炎患者中,fosdagrocorat 10 mg和15 mg显示出与泼尼松10 mg相似的疗效,安全性相似于泼尼松5 mg。
研究设计与样本
- 12周、IIb期、随机、双盲、多中心、安慰剂和阳性对照试验,纳入323例中重度类风湿关节炎患者,按1:1:1:1:1:1:1随机分配至fosdagrocorat 1 mg、5 mg、10 mg、15 mg,泼尼松5 mg、10 mg或安慰剂,每日一次。
主要发现
- 第8周模型预测ACR20应答率:fosdagrocorat 1 mg为47%、5 mg为61%、10 mg为69%、15 mg为73%;泼尼松5 mg为51%、10 mg为71%;安慰剂为37%。
- fosdagrocorat 10 mg和15 mg的ACR20应答优于安慰剂,15 mg不劣于泼尼松10 mg。
- fosdagrocorat 1 mg、5 mg和10 mg的P1NP自基线百分比变化达非劣于泼尼松5 mg的标准,uNTx:uCr相应变化差异较大。
- 所有fosdagrocorat剂量均降低糖化血红蛋白水平。
- 63例(19.5%)患者报告治疗相关不良事件,9例(2.8%)报告严重不良事件;未报告肾上腺功能不全、治疗相关显著感染或实验室异常,无死亡。
关键数值与推荐
- 主要终点为第8周ACR20应答率及骨形成标志物P1NP和骨吸收标志物uNTx:uCr自基线百分比变化。
- fosdagrocorat 10 mg和15 mg的ACR20应答优于安慰剂,15 mg非劣于泼尼松10 mg。
- fosdagrocorat 1 mg、5 mg和10 mg的P1NP变化非劣于泼尼松5 mg。
临床怎么用
- fosdagrocorat 10 mg和15 mg可能作为中重度类风湿关节炎的候选治疗,疗效与泼尼松10 mg相似,安全性特征与泼尼松5 mg相似。
- 治疗期间需监测糖化血红蛋白、骨形成标志物P1NP和骨吸收标志物uNTx:uCr。
局限性
- 研究为12周IIb期试验,长期疗效和安全性未评估。
- uNTx:uCr变化差异较大,骨吸收影响需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Glucocorticoids have anti-inflammatory, transrepression-mediated effects, although adverse events (AEs; transactivation-mediated effects) limit long-term use in patients with rheumatoid arthritis (RA). We evaluated the efficacy and safety of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, versus prednisone or placebo. METHODS: In this 12-week, phase II, randomised controlled trial, 323 patients with moderate to severe RA were randomised 1:1:1:1:1:1:1 to fosdagrocorat (1 mg, 5 mg, 10 mg or 15 mg), prednisone (5 mg or 10 mg) or placebo, once daily. The primary endpoints (week 8) were American College of Rheumatology 20% improvement criteria (ACR20) responses, and percentage changes from baseline in biomarkers of bone formation (procollagen type 1 N-terminal peptide [P1NP]) and resorption (urinary N-telopeptide to urinary creatinine ratio [uNTx:uCr]). Safety was assessed. RESULTS: ACR20 responses with fosdagrocorat 10 mg and 15 mg were superior to placebo, and fosdagrocorat 15 mg was non-inferior to prednisone 10 mg (week 8 model-predicted ACR20 responses: 47%, 61%, 69% and 73% vs 51%, 71% and 37% with fosdagrocorat 1 mg, 5 mg, 10 mg and 15 mg vs prednisone 5 mg, 10 mg and placebo, respectively). Percentage changes from baseline in P1NP with fosdagrocorat 1 mg, 5 mg and 10 mg met non-inferiority criteria to prednisone 5 mg. Corresponding changes in uNTx:uCr varied considerably. All fosdagrocorat doses reduced glycosylated haemoglobin levels. AEs were similar between groups; 63 (19.5%) patients reported treatment-related AEs; 9 (2.8%) patients reported serious AEs. No patients had adrenal insufficiency, treatment-related significant infections or laboratory abnormalities. No deaths were reported. CONCLUSION: In patients with RA, fosdagrocorat 10 mg and 15 mg demonstrated efficacy similar to prednisone 10 mg and safety similar to prednisone 5 mg. TRIAL REGISTRATION NUMBER: NCT01393639.
引用
- Buttgereit F, Strand V, Lee EB, et al. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open. 2019. PMID: 31168411. doi:10.1136/rmdopen-2018-000889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。